Corient Private Wealth
CRMD icon

Corient Private Wealth’s CorMedix CRMD Stock Holding History

Corient Private Wealth’s Portfolio CRMD Stock Details CRMD Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2026
Q2 		$753K Sell
95,940
-1,008
-1% -$7.96K ﹤0.01% 1961
2026
Q1 		$658K Buy
+96,948
New +$717K ﹤0.01% 1879

Other funds holding CRMD

BlackRock
BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return
DTC
Deep Track Capital Greenwich, Connecticut $6.87B AUM 205.24% 1-Year Est. Return
Vanguard Capital Management
Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM
State Street
State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return
UBS Group
UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return
OAM
Oberweis Asset Management Lisle, Illinois $4.84B AUM 160.95% 1-Year Est. Return
Alyeska Investment Group
Alyeska Investment Group Chicago, Illinois $38.9B AUM 28.51% 1-Year Est. Return
Marshall Wace
Marshall Wace London, United Kingdom $127B AUM 46.06% 1-Year Est. Return

Corient Private Wealth's CRMD Position: Q2 2026 in Review

Corient Private Wealth reduced its CorMedix (CRMD) stake by 1% in Q2 2026, selling an estimated $7.96K and leaving 95,940 shares worth $753K. The position accounts for ﹤0.01% of the portfolio, ranked #1961.

Corient Private Wealth first reported a position in CRMD in Q1 2026 and has held it in 2 quarters since. 193 funds tracked by Wall St. Rank hold CRMD as of Q2 2026.

  • Corient Private Wealth held 95,940 shares of CorMedix worth $753K as of Q2 2026.
  • Corient Private Wealth sold 1,008 CorMedix shares in Q2 2026, an estimated $7.96K.
  • CorMedix made up ﹤0.01% of Corient Private Wealth's portfolio in Q2 2026, its #1961 holding.
  • Corient Private Wealth first reported a position in CorMedix in Q1 2026 and has held it in 2 quarters since.
  • 193 funds tracked by Wall St. Rank held CorMedix as of Q2 2026.

Based on Corient Private Wealth's 13F filing for Q2 2026, filed 12 Aug 2026.